AUPH (Aurinia Pharmaceuticals) Cyclically Adjusted FCF per Share: $-0.44 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AUPH Aurinia Pharmaceuticals Inc AUPH
81 GF Score
Price $16.10
GF Value $14.05
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals Cyclically Adjusted FCF per Share?

Aurinia Pharmaceuticals AUPH +0.75% 81 Cyclically Adjusted FCF per Share is $-0.44 as of Mar. 2026. GuruFocus rates AUPH with a GF Score™ of 81/100 and a GF Value™ of $14.05 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Aurinia Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.236. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.44 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Aurinia Pharmaceuticals was 37.20% per year. The lowest was 3.00% per year. And the median was 14.20% per year.

As of today (2026-07-16), Aurinia Pharmaceuticals's current stock price is $16.10. Aurinia Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.44. Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Aurinia Pharmaceuticals  (NAS:AUPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Aurinia Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Aurinia Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.88 -0.76 -0.73 -0.63 -0.48

Aurinia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.63 -0.58 -0.53 -0.48 -0.44

AUPH vs KOD, ABCL, AGIO: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


AUPH
81GF Score
Aurinia Pharmaceuticals Inc AUPH
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aurinia Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Aurinia Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.236/132.2623*132.2623
=0.236

Current CPI (Mar. 2026) = 132.2623.

Aurinia Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.155 102.002 -0.201
201609 -0.116 101.765 -0.151
201612 -0.106 101.449 -0.138
201703 -0.171 102.634 -0.220
201706 -0.169 103.029 -0.217
201709 -0.102 103.345 -0.131
201712 -0.106 103.345 -0.136
201803 -0.171 105.004 -0.215
201806 -0.146 105.557 -0.183
201809 -0.133 105.636 -0.167
201812 -0.160 105.399 -0.201
201903 -0.146 106.979 -0.181
201906 -0.145 107.690 -0.178
201909 -0.128 107.611 -0.157
201912 -0.260 107.769 -0.319
202003 -0.203 107.927 -0.249
202006 -0.202 108.401 -0.246
202009 -0.267 108.164 -0.326
202012 0.008 108.559 0.010
202103 -0.430 110.298 -0.516
202106 -0.295 111.720 -0.349
202109 -0.315 112.905 -0.369
202112 -0.197 113.774 -0.229
202203 -0.331 117.646 -0.372
202206 -0.197 120.806 -0.216
202209 -0.109 120.648 -0.119
202212 0.073 120.964 0.080
202303 -0.226 122.702 -0.244
202306 -0.021 124.203 -0.022
202309 -0.092 125.230 -0.097
202312 0.099 125.072 0.105
202403 -0.129 126.258 -0.135
202406 0.109 127.522 0.113
202409 0.116 127.285 0.121
202412 0.201 127.364 0.209
202503 0.009 129.181 0.009
202506 0.321 129.892 0.327
202509 0.326 130.287 0.331
202512 0.331 130.366 0.336
202603 0.236 132.262 0.236

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.44 mean?
Aurinia Pharmaceuticals (AUPH) has a Cyclically Adjusted FCF per Share of $-0.44 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors.
Is Aurinia Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Aurinia Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-0.44. Overall, Aurinia Pharmaceuticals has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aurinia Pharmaceuticals' Cyclically Adjusted FCF per Share compare to KOD and ABCL?
Aurinia Pharmaceuticals' Cyclically Adjusted FCF per Share of $-0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Aurinia Pharmaceuticals and its competitors. Aurinia Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurinia Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aurinia Pharmaceuticals (AUPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.05, compared to a current price of $16.10 — trading 14.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.44. Aurinia Pharmaceuticals' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Aurinia Pharmaceuticals (AUPH), the current Cyclically Adjusted FCF per Share is $-0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aurinia Pharmaceuticals (AUPH) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of $16.10 is trading 14.6% above its estimated GF Value™ of $14.05. GuruFocus considers Aurinia Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for AUPH:

  • Cyclically Adjusted FCF per Share: $-0.44
  • GF Value™: $14.05 vs. price of $16.10 (14.6% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the AUPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges IKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for AUPH

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.10
Price
$14.05
GF Value